Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A sarcoma that arises from the bone. Representative examples are osteosarcoma and chondrosarcoma. 
Bone sarcomas most frequently harbor alterations in TP53, IDH1, CDKN2A, CDKN2B, and RB1 .
TP53 Mutation, IDH1 Mutation, IDH1 Codon 132 Missense, TP53 c.217-c.1178 Missense, and TP53 Missense are the most common alterations in bone sarcoma .
There are 6 clinical trials for bone sarcoma, of which 4 are open and 2 are completed or closed. Of the trials that contain bone sarcoma as an inclusion criterion, 2 are phase 1 (1 open), 2 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (1 open).
CTAG1A, CTAG1B, and HLA-A*02:01 are the most frequent gene inclusion criteria for bone sarcoma clinical trials .
Ny-eso-1 t cell receptor-activated autologous t cells, anti-ny-eso-1 tcr lv-transduced autologous t-cells taest16001, and atezolizumab are the most common interventions in bone sarcoma clinical trials.
Significant Genes in Bone Sarcoma
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.